Sunantha Sethuraman serves as a Principal Scientist in Clinical Bioinformatics at Repare Therapeutics, where she leverages over 12 years of experience in computational biology to drive innovative solutions in drug development and clinical trials. Her current focus is on lunresertib, a pioneering PKMYT1 inhibitor that...
Sunantha Sethuraman serves as a Principal Scientist in Clinical Bioinformatics at Repare Therapeutics, where she leverages over 12 years of experience in computational biology to drive innovative solutions in drug development and clinical trials. Her current focus is on lunresertib, a pioneering PKMYT1 inhibitor that is being evaluated in multiple clinical trials, both as a standalone treatment and in combination with other therapies, including camonsertib and WEE1 inhibitors. In this role, Sunantha is not only the clinical and translational bioinformatics lead but also a key strategist in the planning and execution of these trials, particularly concerning biomarker identification and real-world evidence (RWE) integration.
Sunantha’s expertise in oncology and cancer genomics positions her at the forefront of translational research, where she utilizes advanced bioinformatics techniques to derive actionable insights from high-dimensional omics data. Her proficiency in R, data visualization, and tools like Docker enhances her ability to analyze complex datasets, ensuring that the findings are both robust and clinically relevant. By employing methodologies such as ChIP-seq and miRNA analysis, she contributes significantly to understanding the molecular underpinnings of cancer and the therapeutic potential of lunresertib.
Her passion for pushing the boundaries of data science applications in the pharmaceutical industry is evident in her collaborative approach, working closely with cross-functional teams to translate bioinformatics findings into tangible clinical outcomes. As she continues to navigate the evolving landscape of drug development, Sunantha remains committed to harnessing the power of data to improve patient outcomes and advance the field of oncology.
